Back to matchesWe found a matchYour institution may have access to this item. Find your institution then sign in to continue.TitlePotential Medicare and Medicaid Savings on Anti-CD20 Therapy for Multiple Sclerosis.AuthorsKim, John; Kesselheim, Aaron S.; Bove, Riley; Avorn, Jerry; Rome, Benjamin N.AbstractThis cross-sectional study compares price data for ocrelizumab and rituximab to estimate the savings to Medicare and Medicaid if rituximab were used in the treatment of multiple sclerosis instead of the higher-priced ocrelizumab.PublicationJAMA Neurology, 2024, Vol 81, Issue 1, p85ISSN2168-6149Publication typeArticleDOI10.1001/jamaneurol.2023.4514